ZLAB Stock Recent News

Shares in the Chinese biopharma firm have been pounded by disappointing trial results for a cancer drug and sluggish sales of its existing products

Zai Lab Limited (NASDAQ:ZLAB ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 2:35 PM EDT Company Participants Ying Du - Founder, Chairperson & CEO Joshua Smiley - President & COO Conference Call Participants Po Han Lin - Morgan Stanley, Research Division Presentation Po Han Lin Equity Analyst Good afternoon, everyone. Thank you for joining us today.

NEW YORK, Sept. 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB).  Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) in Hong Kong for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. “Today's approval of TIVDAK marks an important milestone for Zai Lab, further strengthening our Women's franchise in Greater China,” said Andrew Zhu, Chief Commercial Of.

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conferences in September 2025: Cantor Global Healthcare Conference Presentation: Thursday, September 4, 2025, 10:20 a.m. ET Location: New York, NY Morgan Stanley 23rd Annual Global Healthcare Conference Fireside Chat: Tuesday, September 9, 2025, 2:35 p.m. ET Location: New York, NY Live webcasts wi.

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the China National Medical Products Administration (NMPA) has granted Innovative Medical Device Designation for Tumor Treating Fields (TTFields) for patients with pancreatic cancer based on the positive results from the Phase 3 PANOVA-3 trial. The Innovative Medical Device Designation allows Zai Lab to take advantage of an expedited approval procedure for TTFields that offers opportunit.

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the creation of its Oncology Scientific Advisory Board (SAB). The newly formed Oncology SAB is comprised of distinguished oncology leaders and will support the advancement of the Company's robust oncology products and pipeline, including multiple internally developed investigational therapies. “We are honored to bring together this esteemed group of oncology leaders who will support our cont.

Zai Lab Limited (NASDAQ:ZLAB ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Christine Chiou - Senior VP & Head of Investor Relations Joshua L. Smiley - President & COO Rafael G.

The headline numbers for Zai Lab Limited (ZLAB) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the second quarter of 2025, along with recent product highlights and corporate updates. “Zai Lab is entering a pivotal period – defined by innovation, scale and strong execution,” said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. “We are making meaningful progress throughout our business – expanding patient impact, accelerating global innovation, and opera.